Zipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3...

|By:, SA News Editor

Zipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3 sarcoma drug. The results correlate with positive data reported in February. (PR)